Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Study of Abemaciclib (LY2835219) In Participants With Previously Treated Breast Cancer That Has Spread

ClinicalTrials.gov ID: NCT02102490

Public ClinicalTrials.gov record NCT02102490. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 12, 2026, 7:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Study of LY2835219 for Patients With Previously Treated Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer

Study identification

NCT ID
NCT02102490
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Eli Lilly and Company
Industry
Enrollment
132 participants

Conditions and interventions

Interventions

  • Abemaciclib Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
Female
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 9, 2014
Primary completion
Apr 29, 2016
Completion
Oct 21, 2018
Last update posted
Jan 20, 2020

2014 – 2018

United States locations

U.S. sites
27
U.S. states
13
U.S. cities
25
Facility City State ZIP Site status
Northern Arizona Hematology & Oncology Associates Sedona Arizona 86336
HOPE Hematology Oncology Physicians and Extenders Tucson Arizona 85704
Arizona Clinical Research Center Tucson Arizona 85715
Univ of California San Francisco San Francisco California 94115
Sansum Medical Research Foundation Santa Barbara California 93105
Rocky Mountain Cancer Center Denver Colorado 80220
Washington Hospital Center Washington D.C. District of Columbia 20010
Florida Cancer Specialists Fort Myers Florida 33916
Advanced Medical Specialties Miami Florida 33176
Florida Cancer Specialists St. Petersburg Florida 33705
Maryland Oncology Hematology, P.A. Columbia Maryland 21044
Dana Farber Cancer Institute Boston Massachusetts 02115
Minnesota Oncology/Hematology PA Minneapolis Minnesota 55404
Memorial Sloan Kettering Cancer Center New York New York 10065
Oncology Hematology Care Inc Cincinnati Ohio 45242
Sarah Cannon Research Institute SCRI Nashville Tennessee 37203
Texas Oncology Cancer Center Austin Texas 78731
Texas Oncology - Bedford Bedford Texas 76022
Presbyterian Hospital Dallas Dallas Texas 75231
Texas Oncology-Baylor Charles A. Sammons Cancer Center Dallas Texas 75246
The Center for Cancer and Blood Disorders Fort Worth Texas 76104
Texas Oncology-Memorial City Houston Texas 77024
Texas Oncology-Plano West Plano Texas 75093
Texas Oncology-Sherman Sherman Texas 75090-0504
US Oncology The Woodlands Texas 77380
Tyler Cancer Center Tyler Texas 75702
Northwest Cancer Specialists PC Vancouver Washington 98684

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02102490, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 20, 2020 · Synced May 12, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02102490 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →